Medicina (Sep 2022)

Gastrectomy with or without Complete Omentectomy for Advanced Gastric Cancer: A Meta-Analysis

  • Maurizio Zizzo,
  • Magda Zanelli,
  • Francesca Sanguedolce,
  • Andrea Palicelli,
  • Stefano Ascani,
  • Andrea Morini,
  • David Tumiati,
  • Federica Mereu,
  • Antonia Lavinia Zuliani,
  • Melissa Nardecchia,
  • Francesca Gatto,
  • Manuel Zanni,
  • Alessandro Giunta

DOI
https://doi.org/10.3390/medicina58091241
Journal volume & issue
Vol. 58, no. 9
p. 1241

Abstract

Read online

Background and Objectives: Surgery remains the only possible curative treatment for advanced gastric cancer (AGC). Peritoneal metastases are estimated to occur in approximately 55–60% AGC patients. Greater omentum is the most common metastatic area in AGC. At present, omentectomy alone or bursectomy are usually carried out during gastric cancer surgery. We performed a meta-analysis in order to evaluate long-term and short-term outcomes among AGC patients, who have undergone radical gastrectomy with or without complete omentectomy (CO). Materials and Methods: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Meta-analysis was performed by use of RevMan (Computer program) Version 5.4. Results: The eight included studies covered an approximately 20 years long study period (2000–2018). Almost all included studies were retrospective ones and originated from Asian countries. Meta-analysis indicated gastrectomy without CO as significantly associated with longer 3-year (RR: 0.94, 95% CI: 0.90–0.98, p = 0.005) and 5-year overall survivals (OS) (RR: 0.93, 95% CI: 0.88–0.98, p = 0.007). Moreover, we found longer operative time (MD: 24.00, 95% CI: −0.45–48.45, p = 0.05) and higher estimated blood loss (MD: 194.76, 95% CI: 96.40–293.13, p = 0.0001) in CO group. Conclusions: Non-complete omentectomy (NCO) group had a statistically greater rate in 3-year and 5-year OSs than the CO group, while the CO group had significantly longer operative time and higher estimated blood loss than the NCO group. Further randomized, possibly multi-center trials may turn out of paramount importance in confirming our results.

Keywords